Return to flip book view

HELPFUL PUBLICATIONS Lobular Carcinoma of the Breast: AComprehensive Review with TranslationalInsightsClinicopathological Features and OutcomesComparing Patients With Invasive Ductal andLobular Breast CancerInvasive lobular carcinoma of the breast: theincreasing importance of the special subtypeThis brochure was produced under theguidance of LBCA’s Scientific Advisory Boardand with the input of patient advocates.We envision a world in which lobularbreast cancer is found early, treatedeffectively, and eradicated permanently.Visit the LBCA Publication LibraryWHAT IS PATIENTADVOCACY?Patient Advocates: Individuals who seek tolearn about lobular breast cancer to: Help advance research Help educate others Want to become a patient advocate? Visit LBCA’s advocacy website pagesResearch AdvocacyEducationAdvocacyVisit the LBCA website for moreinformation, resources, and to learnabout volunteering.lobularbreastcancer.org Research Advocacy EducationAdvocacy INFORMATIONABOUT LOBULARBREAST CANCER

IMAGING AND TREATMENTLBCA RESOURCESImaging Because it usually does not form lumps, invasive lobular carcinoma can be hard to feel and to see on imaging. ILC is often found larger when the tumoris already 2 cms, and involves the axillarylymph nodes (in the arm pit).There are not yet specific guidelines forbest detecting initial, or screening forrecurrent ILC tumors.TreatmentHormone therapy is recommended for bothpre- and post menopausal patients withhormone receptor positive ILC. Aromatase inhibitors and tamoxifen are used most commonly. Chemotherapy may be beneficial forsome patients with ILC, but there isongoing research into when it is mosteffective for those with early stagehormone receptor positive disease. WHAT IS LOBULAR BREASTCANCER ? Also known as invasive lobularcarcinoma (ILC), it is the 2nd mostcommon subtype of breast cancerafter invasive ductal carcinoma (IDC). About 15% of all breast cancers diagnosedin the U.S. each year are lobular.ILC is usually hormone receptor-positive(>90% of cases).Lobular tumors metastasize mostcommonly to the liver, lungs, and bones, but can also metastasize to uncommonsites such as the gastrointestinal tract,ovaries, or the lining of the brain(leptomeninges).Despite a generally good prognosis, somestudies suggest an increased risk of laterecurrence (after 5 years).More research is needed to understandrelapse drivers and therapy resistance.Age/GenderMost ILC diagnoses occur in women > age 60Race/Ethnicity73% of ILC diagnoses are non-Hispanic White12% are Hispanic9% are non-Hispanic Black5% non-Hispanic Asian/Pacific Islanders UNDER THE MICROSCOPE* Source: NCI SEER-22. 2016-2020.WHAT IS THE LOBULAR BREASTCANCER ALLIANCE (LBCA)?LBCA is a national nonprofitorganization founded and guided bypatients to address the lack of ILCinformation and research.LBCA is guided by an advisory board ofinternational clinicians and researchers withILC expertise.LBCA provides comprehensive information on ILC through documents and webinars.LBCA helps individuals and scientists worktogether on ILC advocacy and research.Everyone is different. Discuss your imagingand treatment options with your care team.LBCA has resources to help you talkwith your care team and more.Questions for My Doctor*ILC Fact Sheet*Frequently Asked Questions (FAQs)*Information on Metastatic ILC*ILC StoriesEducational VideosInformation on Open ILC Clinical TrialsBreast Cancer Patient Support ILC DEMOGRAPHICS*lobularbreastcancer.org/resources Visit the LBCA Resources Pagefor more information.*available in 15 languagesILC Tumor Cells IDC Tumor CellsVSCells grow in single file formationCells clump together in “lumps”

IMAGING AND TREATMENTLBCA RESOURCESImaging Because it usually does not form lumps, invasive lobular carcinoma can be hard to feel and to see on imaging. ILC is often found larger when the tumoris already 2 cms, and involves the axillarylymph nodes (in the arm pit).There are not yet specific guidelines forbest detecting initial, or screening forrecurrent ILC tumors.TreatmentHormone therapy is recommended for bothpre- and post menopausal patients withhormone receptor positive ILC. Aromatase inhibitors and tamoxifen are used most commonly. Chemotherapy may be beneficial forsome patients with ILC, but there isongoing research into when it is mosteffective for those with early stagehormone receptor positive disease. WHAT IS LOBULAR BREASTCANCER ? Also known as invasive lobularcarcinoma (ILC), it is the 2nd mostcommon subtype of breast cancerafter invasive ductal carcinoma (IDC). About 15% of all breast cancers diagnosedin the U.S. each year are lobular.ILC is usually hormone receptor-positive(>90% of cases).Lobular tumors metastasize mostcommonly to the liver, lungs, and bones, but can also metastasize to uncommonsites such as the gastrointestinal tract,ovaries, or the lining of the brain(leptomeninges).Despite a generally good prognosis, somestudies suggest an increased risk of laterecurrence (after 5 years).More research is needed to understandrelapse drivers and therapy resistance.Age/GenderMost ILC diagnoses occur in women > age 60Race/Ethnicity73% of ILC diagnoses are non-Hispanic White12% are Hispanic9% are non-Hispanic Black5% non-Hispanic Asian/Pacific Islanders UNDER THE MICROSCOPE* Source: NCI SEER-22. 2016-2020.WHAT IS THE LOBULAR BREASTCANCER ALLIANCE (LBCA)?LBCA is a national nonprofitorganization founded and guided bypatients to address the lack of ILCinformation and research.LBCA is guided by an advisory board ofinternational clinicians and researchers withILC expertise.LBCA provides comprehensive information on ILC through documents and webinars.LBCA helps individuals and scientists worktogether on ILC advocacy and research.Everyone is different. Discuss your imagingand treatment options with your care team.LBCA has resources to help you talkwith your care team and more.Questions for My Doctor*ILC Fact Sheet*Frequently Asked Questions (FAQs)*Information on Metastatic ILC*ILC StoriesEducational VideosInformation on Open ILC Clinical TrialsBreast Cancer Patient Support ILC DEMOGRAPHICS*lobularbreastcancer.org/resources Visit the LBCA Resources Pagefor more information.*available in 15 languagesILC Tumor Cells IDC Tumor CellsVSCells grow in single file formationCells clump together in “lumps”

IMAGING AND TREATMENTLBCA RESOURCESImaging Because it usually does not form lumps, invasive lobular carcinoma can be hard to feel and to see on imaging. ILC is often found larger when the tumoris already 2 cms, and involves the axillarylymph nodes (in the arm pit).There are not yet specific guidelines forbest detecting initial, or screening forrecurrent ILC tumors.TreatmentHormone therapy is recommended for bothpre- and post menopausal patients withhormone receptor positive ILC. Aromatase inhibitors and tamoxifen are used most commonly. Chemotherapy may be beneficial forsome patients with ILC, but there isongoing research into when it is mosteffective for those with early stagehormone receptor positive disease. WHAT IS LOBULAR BREASTCANCER ? Also known as invasive lobularcarcinoma (ILC), it is the 2nd mostcommon subtype of breast cancerafter invasive ductal carcinoma (IDC). About 15% of all breast cancers diagnosedin the U.S. each year are lobular.ILC is usually hormone receptor-positive(>90% of cases).Lobular tumors metastasize mostcommonly to the liver, lungs, and bones, but can also metastasize to uncommonsites such as the gastrointestinal tract,ovaries, or the lining of the brain(leptomeninges).Despite a generally good prognosis, somestudies suggest an increased risk of laterecurrence (after 5 years).More research is needed to understandrelapse drivers and therapy resistance.Age/GenderMost ILC diagnoses occur in women > age 60Race/Ethnicity73% of ILC diagnoses are non-Hispanic White12% are Hispanic9% are non-Hispanic Black5% non-Hispanic Asian/Pacific Islanders UNDER THE MICROSCOPE* Source: NCI SEER-22. 2016-2020.WHAT IS THE LOBULAR BREASTCANCER ALLIANCE (LBCA)?LBCA is a national nonprofitorganization founded and guided bypatients to address the lack of ILCinformation and research.LBCA is guided by an advisory board ofinternational clinicians and researchers withILC expertise.LBCA provides comprehensive information on ILC through documents and webinars.LBCA helps individuals and scientists worktogether on ILC advocacy and research.Everyone is different. Discuss your imagingand treatment options with your care team.LBCA has resources to help you talkwith your care team and more.Questions for My Doctor*ILC Fact Sheet*Frequently Asked Questions (FAQs)*Information on Metastatic ILC*ILC StoriesEducational VideosInformation on Open ILC Clinical TrialsBreast Cancer Patient Support ILC DEMOGRAPHICS*lobularbreastcancer.org/resources Visit the LBCA Resources Pagefor more information.*available in 15 languagesILC Tumor Cells IDC Tumor CellsVSCells grow in single file formationCells clump together in “lumps”

HELPFUL PUBLICATIONS Lobular Carcinoma of the Breast: AComprehensive Review with TranslationalInsightsClinicopathological Features and OutcomesComparing Patients With Invasive Ductal andLobular Breast CancerInvasive lobular carcinoma of the breast: theincreasing importance of the special subtypeThis brochure was produced under theguidance of LBCA’s Scientific Advisory Boardand with the input of patient advocates.We envision a world in which lobularbreast cancer is found early, treatedeffectively, and eradicated permanently.Visit the LBCA Publication LibraryWHAT IS PATIENTADVOCACY?Patient Advocates: Individuals who seek tolearn about lobular breast cancer to: Help advance research Help educate others Want to become a patient advocate? Visit LBCA’s advocacy website pagesResearch AdvocacyEducationAdvocacyVisit the LBCA website for moreinformation, resources, and to learnabout volunteering.lobularbreastcancer.org Research Advocacy EducationAdvocacy INFORMATIONABOUT LOBULARBREAST CANCER

HELPFUL PUBLICATIONS Lobular Carcinoma of the Breast: AComprehensive Review with TranslationalInsightsClinicopathological Features and OutcomesComparing Patients With Invasive Ductal andLobular Breast CancerInvasive lobular carcinoma of the breast: theincreasing importance of the special subtypeThis brochure was produced under theguidance of LBCA’s Scientific Advisory Boardand with the input of patient advocates.We envision a world in which lobularbreast cancer is found early, treatedeffectively, and eradicated permanently.Visit the LBCA Publication LibraryWHAT IS PATIENTADVOCACY?Patient Advocates: Individuals who seek tolearn about lobular breast cancer to: Help advance research Help educate others Want to become a patient advocate? Visit LBCA’s advocacy website pagesResearch AdvocacyEducationAdvocacyVisit the LBCA website for moreinformation, resources, and to learnabout volunteering.lobularbreastcancer.org Research Advocacy EducationAdvocacy INFORMATIONABOUT LOBULARBREAST CANCER